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ABSTRACT
Respiratory syncytial virus (RSV) is the main cause of lower respiratory disease in 
infants and children under five years of age. As there is no specific treatment for RSV 
infections, prophylaxis with the specific monoclonal antibody palivizumab (PVZ) has been 
widely recommended for high-risk cases during the RSV season. The present study aimed to 
evaluate the effectiveness of a public prophylaxis program with palivizumab on the incidence 
of hospitalizations for lower respiratory tract infections and RSV in children at high risk for 
severe RSV infections. A retrospective cohort study was carried out with preterm children 
or children under two years of age with chronic lung disease or hemodynamically significant 
congenital heart disease; the children were selected on the basis of their exposure status, 
which was defined as the prophylactic use of palivizumab during the RSV season. Children 
were enrolled retrospectively in two hospitals located in Southern Brazil, from May 2009 to 
August 2016. In a sample of 129 children, 69 (53.5%) received palivizumab and adherence to 
three or more doses was observed in 78%; 60 (46.5%) children did not receive palivizumab. 
PVZ prophylaxis was independently associated with a 66% reduction in hospitalizations 
for any cause (26/69 - 37.7%) in the PVZ group and 34/60 (56.7%) in the control group). A 
52% reduction in hospitalizations due to lower respiratory tract infection was observed in the 
PVZ group (15/69 -21.7%) and 25/60 (41.7%) in the control group. These findings suggest 
that, for the group of studied patients, the adoption of an RSV prophylaxis scheme reached 
the same effectiveness as those described in previous clinical trials.
KEYWORDS: Palivizumab. Respiratory syncytial viruses. Infant health. Comparative 
effectiveness research.
INTRODUCTION
Respiratory syncytial virus (RSV) is one of the main etiological agents of 
infections affecting the lower respiratory tract among infants and children under five 
years of age, and it accounts for nearly 75% of bronchiolitis and 40% of pneumonia 
cases in infants up to one year of age during the RSV season1,2. Usually, the first 
infection progresses as an ordinary cold; however, severe RSV infections are 
responsible for hospitalization and, eventually, the need of mechanical ventilation 
(MV), mostly in children of less than 1 year of age1,3.
As there is no specific treatment for RSV infections, prophylaxis with the 
specific monoclonal antibody palivizumab (PVZ) has been widely recommended 
for high-risk cases during RSV season4. The groups with a higher risk of severe 
respiratory disease caused by RSV are premature infants, children with chronic 
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lung disease of prematurity, immunosuppressed children 
and children suffering from heart conditions, especially 
those with hemodynamic consequences1.
The effectiveness of palivizumab in reducing 
hospitalizations due to RSV in infants has been demonstrated 
in randomized clinical trials, ranging from 39 to 78% in two 
pivotal clinical trials5-7. Evidence from observational studies 
suggests that PVZ prophylaxis reduces the incidence of 
recurrent wheezing over the first six years of life; however, 
it does not prevent the onset of atopic asthma8,9.
In December 2012, PVZ was introduced in the Brazilian 
public health system (SUS) for use in high-risk cases and 
premature infants at a gestational age equal to or less than 
32 weeks10; this decision was amended in 2013, with 
prophylaxis being recommended for infants under one 
year of age who were born prematurely at a gestational 
age equal to or less than 28 weeks, as well as in children 
up to two years of age suffering from chronic lung disease 
or hemodynamically significant congenital heart disease11.
Since the drug was incorporated into SUS, few studies 
have assessed the impact of the use of palivizumab on lower 
respiratory tract infection rates in children at high risk for 
respiratory syncytial virus infections. Post-incorporation 
studies are crucial to monitor the outcomes achieved with 
the use of this approach. The present study aimed to evaluate 
the effectiveness of a public prophylaxis program with 
palivizumab on the incidence of hospitalizations for lower 
respiratory tract infections and RSV cases in children at 
high-risk for severe RSV infections.
MATERIAL AND METHODS
Study design
A retrospective cohort study was conducted. The 
medical records of preterm children and/or children under 
two years of age suffering from chronic lung disease or 
hemodynamically significant congenital heart disease 
were reviewed for data collection. Children were selected 
according to their exposure status, which was defined as 
the prophylactic use of at least one dose of palivizumab 
with monthly doses of palivizumab during the RSV season 
(between April and August). Children were retrospectively 
recruited at the Hospital Materno Infantil Presidente Vargas 
(HMIPV) and Hospital de Clinicas de Porto Alegre – 
RS (HCPA), both located in the city of Porto Alegre, in 
Southern Brazil. Although palivizumab was incorporated 
into the Brazilian public health system in 2013, due to 
the differences among Brazilian regions regarding drug 
acquisition and distribution and the issues of availability of 
electronic medical records in one of the centers, the study 
period started in 2014. The cases (PVZ group) were chosen 
from May 2014 to August 2016, a period subsequent to the 
incorporation of palivizumab into SUS, and controls were 
chosen from May 2009 to August 2016. The initial date 
for the controls recruitment was extended to include the 
period prior to PVZ incorporation due to the difficulty in 
gathering a sufficient number of children with indication 
but who did not take PVZ after 2014, in the health services 
assessed. The follow-up was censored in June 2017. The 
study period was up to two years following the first dose of 
palivizumab for exposed cases or up to two years after the 
identification of the indication criterium for the use of PVZ 
in the medical records, as recommended by the Ministry of 
Health for controls.
The study included children who met one of the 
following three criteria: 1) prematurity, defined as a 
gestational age at birth ≤ 28 weeks; 2) less than two years 
of age with chronic lung disease resulting from prematurity; 
or 3) less than two years of age with hemodynamically 
significant congenital heart disease.
The list of children who received palivizumab was 
elaborated according to palivizumab dispensation records 
from the hospital pharmacies. Children in the control 
group were identified from the medical records of children 
hospitalized in neonatal or pediatric units during the study 
period, as indicated by International Classification of 
Diseases codes for prematurity or chronic lung disease 
resulting from prematurity or congenital heart disease. 
Children transferred from other health services were 
excluded.
Outcomes were assessed by analyzing data from the 
medical records according to the diagnosis made in the 
health service unit by the attending physician. The outcomes 
were grouped into four categories: 1) hospitalization for 
any reason (hospitalization rate); 2) hospitalization for 
lower respiratory tract infection regardless of etiology (ICD 
10: J20 – J22); 3) hospitalization for respiratory syncytial 
virus infection (ICD 10: B97.4, J12.1, J20.5, or J21.0) and 
4) death from any cause.
Sample size and data analysis
The sample size was calculated using the EPI-INFO 
software, version 7.2, considering the following parameters 
for a cohort study: 80% test power; 95% confidence level 
(α = 5); an expected risk value to be detected of 0.6; and 
an expected emergency admission rate due to respiratory 
causes among the unexposed of 64% according to the 
pilot study conducted at the HCPA. The total sample size 
calculated based on these parameters was 134 (67 exposed 
and 67 unexposed).
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A descriptive analysis on the frequency distribution 
of risk factors was carried out according to the exposure 
groups in the cohort. Student’s t test was used to compare 
the means for some characteristics between the PVZ and 
control groups.
As the cohort groups had different years of inclusion as 
it was difficult to find children with indications for the use 
that were not using prophylaxis after PVZ was incorporated 
into SUS, it was decided that the year of entry into the cohort 
would be included as an independent variable to be tested.
A logistic regression analysis was performed to identify 
predictors of hospitalization. The variables that were 
significant in the bivariate analysis (with a p-value ≤ 0.25) 
were included in the multivariate logistic regression 
model. Backward and Irtest multivariate analyses were 
performed after the removal of each variable to verify 
whether this procedure had an impact on the model. The 
odds ratio (OR), relative risks (RR) and 95% confidence 
intervals were calculated. The data were entered into and 
stored in REDCap (Research Electronic Data Capture) and 
analyzed using STATA software, version 11.2 (Stata-Corp 
LP, College Station,Texas, USA). The study was approved 
by the ethics committees of Hospital Materno Infantil 
Presidente Vargas and Hospital de Clinicas de Porto Alegre.
RESULTS
One hundred and twenty-nine children were included in 
the study; 69 (53.5%) were exposed to palivizumab (cases) 
and 60 (46.5%) were in the unexposed group (controls). 
Most children (91/129 - 70.5) were included based on a 
gestational age equal to or less than 28 weeks and six days, 
followed by those with less than two years of age and with 
chronic lung disease of prematurity (28/129 - 21.7%), less 
than two years of age and suffering from heart disease 
and severe lung hypertension (7/129 - 5.4%), and those 
with more than two years of age suffering from complex 
congenital heart disease (3/129 - 2.3%). Seventy nine 
children lived in the city of Porto Alegre (61.2%), 106 
were born from single pregnancies (82.2%) and 91(70.5%) 
were breastfed. For the city of residence, there was a 
difference between the groups, as most of the unexposed 
(36/60 - 60%) lived in other cities, while those who received 
PVZ (55/69 - 79.7%) were mostly Porto Alegre residents 
(p<0.001). The control group children were less breastfed 
(38/53 - 71.7%) than the group receiving palivizumab 
(53/58 - 91.4%) (p<0.01). Clinical and demographic 
characteristics are shown in Table 1.
Of the 69 children who received palivizumab, 28 
(40.6%) received five doses, 13 (18.8%) received four doses, 
13 (18.8%) received three doses, 13 (18.8%) received two 
doses, and two (2.9%) received one dose. It was noted that, 
in some cases, the first dose was taken up to three months 
after the beginning of the RSV season. Among patients who 
received palivizumab, 46 (66.7%) received all the necessary 
doses during the RSV season, 11 (15.9%) missed only one 
month, and the remainder 12 (17.4%) missed two months 
or more during the RSV season. Side effects were recorded 
in three (4.3%) children: a case of apnea with cyanosis, a 
case of low fever after the administration of the first dose 
(37.4 °C ), and a case of cutaneous rash.
Analysis of hospitalization for any cause
Among children who did not receive palivizumab, 34 
(56.7%) were hospitalized during the follow-up, and among 
those who received palivizumab, 26 (37.7%) children were 
hospitalized (p=0.024). The mean hospital length of stay 
Table 1 - Demographic and clinical characteristics of children meeting the criteria for the use of palivizumab, treated at Hospital 







Age at PVZ indication
     months 7.33 3.67 0.000
Weight at birth
     grams 1.177 1.059 0.188
Gestational age at birth
     weeks 29.24 29.14 0.855
Number of people in household 4.39 4.71 0.401
Length of stay in the neonatal ICU
     days 78.7 77.0 0.825
*P from Student’s t test
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in the palivizumab group was 9.54 days, and in the control 
group, it was 8.75 days (p=0.81). Among hospitalized 
patients, only five children needed mechanical ventilation, 
three from the control group and two from the PVZ group. 
The mean mechanical ventilation time was 6.3 days for the 
controls and 3.0 days for those who received palivizumab 
(p=0.12).
The main reason for hospitalization was broncho-
pneumonia, which was responsible for 23.3% of the total 
hospitalizations (14/60), followed by acute bronchiolitis 
(10/60 - 16.7%), acute bronchitis (6/60 - 10%), acute 
bronchiolitis caused by RSV (6/60 or 10%), and asthma 
(5/60 - 8.3%). All other reasons for hospitalization 
accounted for only one case (1/60 - 1.7 %) each.
The incidence rate of hospitalization for any cause 
was 45.7 per 100 people/year (95% CI: 35.5-58.9). In the 
group of children who did not take palivizumab (control 
group), the density of hospitalization incidence was 59.2 per 
100 people/year (95% CI: 42.3-82.9), and in the children 
who used palivizumab, it was 35.2 per 100 people/year 
(95% CI: 23.9-51.7).
Table 2 shows the bivariate analyses of variables 
associated with hospitalization for any cause. There was no 
association between the year of entry into the cohort and 
hospitalization for any cause, indicated by a p-value > 0.25 
(p= 0.879); therefore, this variable was not included in the 
multivariate model (data not shown in the table).
Table 3 shows the final result of the multivariate model 
for predictors of hospitalization for any cause. The variables 
with p ≤ 0.25 were added to the saturated model and 
then removed one by one from the model as the p-value 
increased, until only those that were statistically significant 
(p < 0.05) remained. Only the use of palivizumab remained 
in the final model as a significant variable.
There was no difference in the number of doses of 
PVZ between children hospitalized for any reason (mean 
of 3.73 doses) and those that were not hospitalized (mean 
of 3.77 doses; p= 0.91).
Table 2 - Bivariate analysis of parameters associated with hospitalization for any cause in children with indication for the use of 
palivizumab, Porto Alegre, 2017.
Hospitalization for any cause




Use of prophylactic palivizumab
     Yes 26 (37.7) 43 (62.3) 1.0
     No 34 (56.7) 26 (43.3) 0.46 (0.23 - 0.94) 0.032
Sex
     Female 32 (45.7) 38 (54.3) 1.0
     Male 28 (47.5) 31 (52.5) 1.07 (0.54 - 2.15) 0.843
Place of residence
     Porto Alegre 35 (44.3) 44 (55.7) 1.0
     Another city 25 (50.0) 25 (50.0) 1.26 (0.62 - 2.56) 0.528
Number of people in household
     Up to 3 people 09 (37.5) 15 (62.5) 1.0
     4 people or more 22 (37.9) 36 (62.1) 1.02 (0.38 - 2.72) 0.971
Main reason for inclusion in the study
     Prematurity 46 (50.5) 45 (49.5) 1.0
     Lung or heart disease 14 (36.8) 24 (63.2) 0.57 (0.26 - 1.24) 0.157
Breastfeeding records
     Yes 43 (47.2) 48 (52.8) 1.0
     No 09 (45.0) 11 (55.0) 0.91 (0.34 - 2.41) 0.855
For those who used PVZ:
Number of doses administered
     Three or more 21 (38.9) 33 (61.1) 1.0
     Up to two 05 (33.3) 10 (66.7) 0.78 (0.23 – 2.62) 0.695
*Adjusted per year of entry into the study
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Analysis of hospitalization due to lower respiratory 
tract infections
Among the children using palivizumab, hospitalizations 
for lower respiratory tract infections were noted in 21.7% 
(15/69), while in those who did not receive palivizumab, 
hospitalizations were observed in 41.7% (25/60) (p=0.01). 
The incidence rate of hospitalization for lower respiratory 
tract infection was 26.0 per 100 people/year (95% CI: 
19.1 - 35.5). In children who did not take palivizumab 
(control group), the density of hospitalization incidence 
was 35.3 per 100 people/year (95% CI: 23.9 - 52.2), and in 
the children who used palivizumab, the calculated rate was 
18.1 per 100 people/year (95% CI: 10.9 - 30.0).
Table 4 shows the bivariate analyses of elements possibly 
associated with hospitalization for lower respiratory tract 
Table 3 - Final multivariate analysis of the association between hospitalization for any cause and exposure elements of individuals, 
Porto Alegre, 2017.
Odds Ratio and 
95% CI
p
Relative Risk and 
95% CI
p PAF
Use of prophylactic palivizumab
     Yes 1.0 1.0
     No 0.46 (0.23 - 0.94) 0.032 0.66 (0.46 -0.97) 0.031 -0.50
PAF = Population Attributable Fraction
Table 4 - Bivariate analysis of parameters associated with hospitalization for lower respiratory tract infections in children with 
indication for the use of palivizumab, Porto Alegre, 2017.
Hospitalization for lower respiratory tract 
infections





Use of prophylactic palivizumab
     Yes 15 (21.7) 54 (78.3) 1.0
     No 25 (41.7) 35 (58.3) 0.39 (0.18 - 0.84) 0.016
Sex
     Female 24 (34.3) 46 (65.7) 1.0
     Male 16 (27.1) 43 (72.9) 0.71 (0.33- 1.52) 0.381
Place of residence
     Porto Alegre 21 (26.6) 58 (73.4) 1.0
     Another city 19 (38.0) 31 (62.0) 1.69 (0.79 - 3.61) 0.174
Number of people in household
     Up to 3 people 04 (16.7) 20 (83.3) 1.0
     4 people or more 16 (27.6) 42 (72.4) 1.90 (0.56 - 6.44) 0.300
Main reason for inclusion in the study
     Prematurity 31 (34.1) 60 (65.9) 1.0
     Lung or heart disease 09 (23.7) 29 (76.3) 0.60 (0.25 - 1.42) 0.248
Breastfeeding records
     Yes 29 (31.9) 62 (68.1) 1.0
     No 07 (35.0) 13 (65.0) 1.15 (0.41 - 3.19) 0.787
For those who used PVZ:
Number of doses administered
     Three or more 11 (20.4) 43 (79.6) 1.0
     Up to two 04 (26.7) 11 (73.3) 1.42 (0.38 - 5.33) 0.602
*Adjusted per year of entry into the study
Batista et al.
Rev Inst Med Trop São Paulo. 2021;63:e5Page 6 of 8
infections. The bivariate analysis of the association between 
the year of entry into the cohort and hospitalization for 
lower respiratory tract infections showed a p value > 0.25 
(p = 0.43); thus, it was not a candidate for inclusion in the 
multivariate model (data not shown in the table).
Table 5 shows the results of the final multivariate 
analysis model for the association between the studied 
parameters and hospitalization for lower respiratory tract 
infections. Variables were removed from the model as the 
p-value increased until only the statistically significant ones 
remained (p < 0.05).
Six hospitalizations with laboratory confirmation 
of respiratory syncytial virus infections were recorded, 
all of which were in the control group. The rate of 
respiratory syncytial virus infection in the cohort was 
3.2 per 100 people/year (95% CI: 1.42-7.04). As this was 
a retrospective study, RSV infection was only considered 
when the diagnosis was recorded in the medical records, 
and it is not possible to know whether all the patients were 
actually tested for RSV, as this is a retrospective study. 
General analysis of the sample
The use of palivizumab remained independently associated 
with hospitalization for any cause and hospitalization for 
lower respiratory tract infections, was a protective factor, 
with relative risk reductions of 66% and 52%, respectively. 
The population attributable fraction associated with the use 
of palivizumab for hospitalizations for any cause was –0.50 
and for hospitalization for lower respiratory tract infections 
was –0.59; that is, it is estimated that palivizumab decreases 
hospitalizations for any cause by 50% and hospitalizations 
for lower respiratory tract infections by 59%.
Only one death was observed in the cohort, and it 
occurred 1.2 years after the date of inclusion; this child 
was in the control group. The death rate in the cohort was 
3.7 per 1,000 people/year (95% CI: 0.53-26.6).
DISCUSSION
Palivizumab prophylaxis was independently associated 
with a reduction in hospitalizations for any cause and 
hospitalization due to lower respiratory tract infections in 
patients at high risk of RSV infection.
The two-year rate of hospitalization for any cause in 
the cohort was 46.5% and it is noteworthy that this was a 
more vulnerable group, given that children were premature 
and/ or suffered from pulmonary or cardiacdiseases. The 
hospitalization rate among those who did not receive 
palivizumab was higher for both, hospitalizations for any 
cause (56.7%) and hospitalizations for lower respiratory 
tract infections (41.7% versus 31%). These findings are 
corroborated by the result of the multivariate analyses 
as well as the calculation of the population attributable 
fraction, according to which, palivizumab reduced 
hospitalizations for any cause by 50% and hospitalizations 
for lower respiratory tract infections by 59%.
The rate of hospitalization for lower respiratory tract 
infections among those who received palivizumab (21.7%) 
was higher than the rate of hospitalization for acute 
respiratory tract infections (12.9%) described in Canada 
during the 2004 and 2005 seasons12. It is important to stress 
that regarding the children who received palivizumab that 
we assessed, the first dose was administered up to three 
months after the beginning of the RSV season, which 
may indicate a delay in palivizumab prescription or in 
the patient’s visit to the referral center after receiving the 
palivizumab prescription at the original hospital. 
The effectiveness of palivizumab in reducing 
hospitalization due to respiratory syncytial virus was shown 
in the IMpact-RSV study6, a randomized double-blind 
clinical trial that included 1,502 premature children (up to 
35 weeks of gestational age) or with bronchopulmonary 
dysplasia; the trial was conducted in the United States, United 
Kingdom and Canada in the late 1990s. In that trial, a 55% 
decrease in hospitalizations for RSV was observed in the 
group treated with palivizumab (4.8%) compared with the 
group that received placebo (10.6%). The hospitalization 
rate for RSV in the placebo group of the IMpact-RSV study 
was similar to the rate found in those unexposed to PVZ in 
our study, which was 10%. In another multicenter clinical 
trial5, a relative decrease of 45% in hospitalizations for RSV 
resulting from the use of palivizumab was described. A 
systematic review carried out in 2011 has also evaluated the 
Table 5 - Final multivariate analysis of the association between hospitalization for lower respiratory tract infections and exposure 
elements of individuals, Porto Alegre, 2017.
Odds Ratio and 
95% CI
p
Relative Risk and 
95% CI
p PAF
Use of prophylactic palivizumab
Yes 1.0 1.0
No 0.39 (0.18 - 0.84) 0.016 0.52 (0.30 - 0.89) 0.014 -0.59
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RSV hospitalization rate among groups who received PVZ, 
the summarized measure of which was 0.35 for the premature 
infants group (p < 0.001)13. Although it was not possible to 
assess the reduction in RSV-specific hospitalizations in this 
study as this outcome did not occur in the exposed group, the 
observed data indicate that the use of palivizumab decreases 
hospitalizations for any cause by 50%.
The clinical trials comparing exposure to palivizumab 
with the use of placebo in the literature are international 
studies with different realities in terms of respiratory 
infection profiles. The studies that provided the basis for 
indicating the incorporation of palivizumab by CONITEC 
were published prior to 2010, and little has been done after 
this incorporation, especially in view of the ethical issue 
that makes it difficult to gather/ form a control group. In 
Brazil, studies on the topic are scarce, and our results 
can only be compared with the cohort study conducted 
by Monteiro et al.1, in 2014 with patients subjected to 
palivizumab prophylaxis; this study was performed without 
a control group for ethical reasons. Among the children who 
received palivizumab, the rate of hospitalization for lower 
respiratory tract infections was 9.1%1, a much lower rate 
than that found in this study (21.7%). The Southern region 
of the country may present a different respiratory infection 
profile due to climate characteristics, with a more distinct 
winter and lower temperatures, as well as to an increase in 
the seasonality of RSV and other respiratory viruses.
As this was a retrospective study, it was not possible to 
ensure that all patients with acute lower respiratory tract 
infections underwent laboratory tests for respiratory syncytial 
virus, which may explain the low rate of RSV-positive 
infections among the patients with bronchiolitis, bronchitis 
and bronchopneumonia (16.7%). This percentage is much 
lower than the rate found by Souza in Porto Alegre14, 
who identified RSV in 59% of samples from infants up 
to 12 months of age with bronchiolitis; unfortunately, 
these patients were recruited between September 2009 
and August 2011, prior to the incorporation of PVZ by the 
public health system.
There was a difference in the mean age of the patients 
chosen for the cohort, with the group using palivizumab 
being in general older than the unexposed group. This 
difference may have resulted from the fact that the controls 
were included upon the observation of the indication of 
palivizumab in accordance with criteria specified by the 
Brazilian Ministry of Health, while the cases that received 
palivizumab were included from the date of the first dose, 
which indicates the date of initial exposure to the drug under 
study. As there is a difference between the date of prescription 
and the first date the drug was administered, especially 
because the only referral hospital for the treatment with 
palivizumab was the HMIPV, there may have been a delay 
in the patient’s visit to this specialized service. At the HCPA, 
the doses were administered only to hospitalized patients, 
while outpatients were referred to the HMIPV.
Another difference found between the exposure groups 
was related to the patients’ cities of residence. Most children 
in the group unexposed to palivizumab (60%) lived in cities 
other than the capital city Porto Alegre. 
The hospitals included in this study are referral 
hospitals located in the metropolitan area of Porto Alegre. 
The unexposed patients from other cities may have risen 
questions about the prescription and the use of palivizumab 
in hospitals located in their home cities; however, to avoid 
this bias, only patients with at least two years of outpatient 
follow-up at the referral hospital and frequent visits were 
selected to ensure that their medical records really included 
information on medications occasionally administered in 
their cities of residence.
An important point in the monitoring of new components 
incorporated into the public health system should take into 
account the cost of prophylaxis in relation to the benefits it 
offers, ideally through a complete cost-effectiveness study. 
It would be important to analyze the increase in drug costs to 
the budget of the public health system, taking into account 
favorable outcomes, such as a decrease in hospitalizations 
and problems for patients and their families. Unfortunately, 
these economic issues were not analyzed in this study and 
should be addressed in future research.
The limitations of the study were those inherent to the 
retrospective cohort study design itself, such as the inability 
to retrospectively collect some variables that are possibly 
association confounders (in this case, socioeconomic 
variables). Regarding the external validity, this study produced 
specific results as it was conducted at referral hospitals and in 
a capital city located in the Southern region of the country, 
where seasonality is well defined and high incidence levels 
of respiratory infections are often experienced in winter, what 
makes this region stand out from the rest. 
CONCLUSION
The use of PVZ has been approved in several 
countries, although its effectiveness is controversial in 
developing countries and in places with a low incidence of 
respiratory infections. In Brazil, there were many questions 
regarding the effectiveness of this drug for the Brazilian 
population at the time of its recommendation in view of 
sociodemographic, epidemiological and even geographical 
differences. This study sought to address a key aspect of 
monitoring the incorporation of new concepts into the public 
health system in an attempt to reinvigorate the process 
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based on the successes and mistakes resulting from the 
decisions made. The results suggest that the adoption of this 
prophylactic program achieved the expected effectiveness 
for the studied patients corroborating the findings of 
previously published international clinical trials.
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